Evoke Pharma, Inc. Reports Second Quarter 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Evoke Pharma (EVOK) Reports Q2 Loss of $0.93/sh
August 13, 2024 8:15 AM EDTEvoke Pharma (NASDAQ: EVOK) reported Q2 EPS of ($0.93), versus ($6.71) reported last year. Revenue for the quarter came in at $2.55 million, versus $1.13 million reported last year.
Based on net sales generated in the first two quarters of 2024, Evoke is revising its 2024 guidance... More